Clinical Trial Update: A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin [Phase 3]

View source ↗

Summary

A 24-week open-label phase 3b trial with a 28-week extension evaluated saxagliptin co-administered with dapagliflozin versus insulin glargine in type 2 diabetes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• Insulin Glargine (insulin glargine)
• Saxagliptin (saxagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2018-09-18